source
- Lilly's oral GLP-1 pill Foundayo reduces sleep apnea events in late-stage trialsIn two late-stage trials, Eli Lilly’s oral GLP‑1 pill Foundayo lowered the apnea‑hypopnea index by an average of 17.8 events per hour, compared with a 4.5‑event reduction for patients on placebo.…
- Phase II success does not guarantee easy Phase III launch, says Thermo FisherPositive Phase II data often signals the start of Phase III planning, but the transition involves far more than simply adding patients and sites. When a trial expands into new countries, differenc…